Bayer Healthcare Pharmaceuticals, Germany
Bayer HealthCare Pharmaceuticals is the pharmaceutical division of Bayer HealthCare AG. We market our products in more than 100 countries, and in 2010 generated sales of almost € 11 billion. More than 38,000 members of staff currently work for Bayer HealthCare Pharmaceuticals worldwide – more than 6,200 in research and development alone. We aim to improve people's quality of life with our products. To achieve this, we concentrate on the research and development of innovative drugs and novel therapeutic approaches. At the same time, we are constantly improving established products. In this context, Bayer HealthCare Pharmaceuticals uses experience it has gained from over a century in the business.
We concentrate on the following therapeutic groups in which we want to make essential contributions to medical progress:
- Cardiovascular and blood diseases
- Oncological diseases
- Gynecological therapies
At the company headquarters in Berlin, Germany, research and development activities in oncology are supported by over 500 scientists and support personnel, covering all aspects of drug development from target discovery up to conduct of pivotal Phase III trials for product registration. The work of the OncoTrack consortium is supported by the Therapeutic Research Group Oncology, responsible for drug discovery and preclinical pharmacology, and the Translational Sciences department within Clinical Pharmacology, responsible for conduct of biomarker analyses in early stage clinical development programs.
- Dr. David Henderson, Principal Scientist in Translational Sciences at Bayer HealthCare Pharmaceuticals